March 21, 2019
Enzyvant to get RVT-801 available to Farber disease patients as quickly as possible after FDA’s nod
Enzyvant’s RVT-801, an investigational enzyme replacement therapy, was granted Rare Pediatric Disease and Fast Track designations by the FDA, the company said in a press release Thursday.